Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LB03002 in adults with growth hormone deficiency
NCT00294619Phase 3Completed
- Sponsor
- LG Chem
- Start
- Apr 2006
- Primary completion
- Mar 2008
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in growth hormone deficiency (GHD) comparing LB03002 with Placebo (2 arms). Primary endpoint: Change in Fat Mass from Baseline at 26 weeks. Started Apr 2006; status: completed.
02
Drugs
Eutropin Plus
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on NCT00294619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00294619.